Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts

Krishan Kumar · Simon Wigfield · Harriet E. Gee · Cecilia M. Devlin · Dean Singleton · Ji-Liang Li · Francesca Buffa · Melanie Huffman · Anthony L. Sinn · Jayne Silver · Helen Turley · Russell Leek · Adrian L. Harris · Mircea Ivan

Received: 7 November 2012 / Revised: 20 December 2012 / Accepted: 2 January 2013 / Published online: 30 January 2013
© Springer-Verlag Berlin Heidelberg 2013

Abstract Inhibition of vascular endothelial growth factor increases response rates to chemotherapy and progression-free survival in glioblastoma. However, resistance invariably occurs, prompting the urgent need for identification of synergizing agents. One possible strategy is to understand tumor adaptation to microenvironmental changes induced by antiangiogenic drugs and test agents that exploit this process. We used an in vivo glioblastoma-derived xenograft model of tumor escape in presence of continuous treatment with bevacizumab. U87-MG or U118-MG cells were subcutaneously implanted into either BALB/c SCID or athymic nude mice. Bevacizumab was given by intraperitoneal injection every 3 days (2.5 mg/kg/dose) and/ or dichloroacetate (DCA) was administered by oral gavage twice daily (50 mg/kg/dose) when tumor volumes reached 0.3 cm³ and continued until tumors reached approximately 1.5–2.0 cm³. Microarray analysis of resistant U87 tumors revealed coordinated changes at the level of metabolic genes, in particular, a widening gap between glycolysis and mitochondrial respiration. There was a highly significant difference between U87-MG-implanted athymic nude mice 1 week after drug treatment. By 2 weeks of treatment, bevacizumab and DCA together dramatically blocked tumor growth compared to either drug alone. Similar results were seen in athymic nude mice implanted with U118-MG cells. We demonstrate for the first time that reversal of the bevacizumab-induced shift in metabolism using DCA is detrimental to neoplastic growth in vivo. As DCA is viewed as a promising agent targeting tumor metabolism, our data establish the timely proof of concept that combining it with antiangiogenic therapy represents a potent antineoplastic strategy.

Keywords Dichloroacetate · Hypoxia · Bevacizumab · Oxidative phosphorylation · Glycolysis

Introduction

Molecular therapies targeting neo-angiogenesis and, in particular, vascular endothelial growth factor (VEGF) have shown
antitumor activity in a variety of clinical contexts [1]. Glioblastoma (GBM) is a highly vascularized and lethal primary brain tumor, with median survival of approximately 12–14 months, and therefore, represents an important target for antiangiogenic drugs [2]. Bevacizumab, a humanized anti-VEGF antibody, is currently approved by the Food and Drug Administration as a second-line treatment of GBM, and ongoing clinical trials aim at assessing its potential as a first-line agent [3]. However, as VEGF blockade prolongs progression-free survival but not overall survival, it is imperative to identify strategies that increase its impact and delay the onset of resistance [4]. For example, limited progress has been achieved in combination with irinotecan; however, no impact on overall survival could be demonstrated [5]. One major limitation in developing synergistic combinations centered on anti-VEGF agents is lack of robust clinical data as tumors that are becoming resistant to these agents are not routinely available for further analyses. Moreover, the cellular and molecular consequences of anti-VEGF treatment are still insufficiently understood. Detailed information at the molecular level on how bevacizumab affects GBM during an extended timeframe is not only essential to our understanding of tumor adaptive responses and subsequent treatment failure but also to the development of rational combination therapies.

We, therefore, sought to determine the tumor response to bevacizumab at the phenotypic and molecular level in xenograft models derived from GBM cell lines. By extending the models until eventual therapeutic failure despite continuous bevacizumab treatment, we aimed to capture the tumor adaptive programs and the corresponding rewiring of the molecular pathways using microarray analysis. We hypothesized that the core mechanisms of resistance would be reflected in alteration of these pathways, and small molecules which interfere with these processes represent realistic candidates to increase the potency of bevacizumab. Bioinformatic analysis revealed that resistant tumors exhibit a strong hypoxia-inducible factor (HIF) signature and shift from mitochondrial respiration to glycolysis. Reactivation of mitochondrial respiration with the orphan drug dichloroacetate (DCA) enhances the transient effect of bevacizumab, in contrast to the lack of additive effect of 2-deoxyglucose (2-DG), which primarily targets glycolysis. Our data provide insights into the plasticity of tumor metabolism in response to therapeutic challenges and suggest novel opportunities for synergistic interventions.

**Materials and methods**

**In vivo tumorigenicity**

All protocols were carried out under Indiana University Institutional Animal Care and Use Committee, and UK Home Office approved protocols and regulations. $10^7$ U87-MG cells (purchased from ATCC) were implanted into 6- to 8-week-old female BALB/c SCID mice (Harlan Sprague Dawley, Inc.) subcutaneously, as 100-μL cell suspensions with an equal volume of Matrigel (BD Bioscience). Tumors were measured twice a week with a caliper, and volumes were calculated using the formula length×width×height×0.52. Once the tumor volume reached 150 mm$^3$, mice were randomized into two groups with starting cohort sizes of five mice per group and treatment of bevacizumab (Roche) injected intraperitoneally every 3 days at a dose of 10 mg/kg or saline control begun. Treatment was continued until tumors grew to approximately a volume of 600–800 mm$^3$ at which point the mice were euthanized and tumors were surgically excised quickly. For the athymic nude mice xenograft models, either U87-MG cells were implanted as above into 4- to 8-week-old female mice (Harlan Laboratories, Indianapolis, IN, USA), or $7 \times 10^6$ U118-MG cells (purchased from ATCC) were grafted. Tumor fragments were either processed by formalin fixation before paraffin embedding for IHC or frozen for later RNA extraction, as described previously [6].

**Drug delivery protocols for combination studies**

DCA was administered by oral gavage twice daily at 50 mg/kg/dose in sterile water (vehicle control was sterile water). This dose was based on published reports and allometric scaling. Thus, 100 mg/kg per mouse per day translates into approximately 13 mg/kg in humans (http://home.fuse.net/clymer/minor/allometry.html), which is consistent with the doses used in clinical settings. Bevacizumab was given intraperitoneally at a concentration of 2.5 mg/kg/dose (U87-MG) or 2.0 mg/kg/dose (U118-MG). Treatment was continued until tumors grew to approximately 20 mm in diameter at which point the mice were euthanized and tumors quickly excised. 2-Deoxyglucose (Sigma, 500 mg/kg) was delivered via intraperitoneal injection daily.

The details of cell culture, gene array analysis, histological analysis and immunohistochemistry, DCA-treated spheroids, and RNA isolation and quantitative RT-PCR (QPCR) analysis are described in the Electronic supplementary material.

**Statistical analysis**

Statistical significance of observed differences among different experimental groups was calculated using a two-tailed $t$ test. $P$ values <0.05 were considered to be statistically significant.

**Results**

Establishment of the bevacizumab-resistance tumor model

U87-MG cell suspensions were subcutaneously injected into the right flank of SCID mice. Treatment with bevacizumab...
(intraperitoneal injection of 10 mg/kg every 3 days) was initiated when tumors averaged 100–200 mm³. Divergence between the treated and non-treated cohorts was evident 1 week later, and at approximately day 40, complete resistance to bevacizumab was achieved (Fig. 1). Tumors were excised separately for controls and treated cohorts at time points when their average growth rates and sizes were similar. An analogous response (i.e., initial response followed by resistance) was observed using a submaximal dose of bevacizumab (2.5 mg/kg; every 3 days by intraperitoneal injection) in athymic nude mice. This will be described in detail as part of the combination studies below.

By performing immunohistochemistry for standard vascular markers (CD31 and CD34) followed by microvessel density

Fig. 1 Analysis of bevacizumab-treated U87-MG tumors. (a) Tumor growth of U87-MG in vivo, treated with bevacizumab (BVC) or vehicle control (CTRL), started from day 12 to the end of the experiment. mean±SE, N=5. Double asterisk (** P<0.01. (B) Immunohistochemical staining of tumor sections from CTRL or BVC-treated tumors show increased hypoxia using HIF-1 and CA9, and a marker of vessel morphology using CD34. Main images are ×10 magnification and inset images ×20 magnification. Sections were stained and scored for (C) vessel Q (CD31), (D) CA9 levels, and (E) necrosis. Mean±SE. Single asterisk (*) P<0.05; triple asterisk (***) P<0.001.
counting, we confirmed that resistant tumors exhibit a significantly sparser vasculature (Fig. 1). Therefore, therapeutic resistance does not appear to be primarily related to renewed vascularization due to a switch to alternative angiogenic growth factors, as shown in other models of bevacizumab resistance [7]. Expression of HIF-1α, as well as of carbonic anhydrase IX (CA9), a robust HIF target and well-established marker of hypoxia, was dramatically increased in the resistant tumors, indicating that their growth continued in a significantly more oxygen-depleted environment consistent with the data reported by Rapisarda et al. [8].

Molecular characterization of bevacizumab-resistance model

In order to gain a comprehensive understanding of the molecular processes that are associated with and potentially critical for the resistance process, total RNA from treated and non-treated tumors was subjected to expression analysis using HGU133plus2 Affymetrix arrays. The full data set for the Affymetrix array expression analysis is available at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37956. A central theme in the bevacizumab-resistant tumors was the coordinated activation of the HIF-driven transcription program (Fig. 2). A large proportion of HIF targets exhibited coordinated upregulation, in most cases with more than one array probe. Notably, glycolytic HIF targets including aldolases A and C, triosephosphate isomerase 1, and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, as well as the inducible glucose transporters GLUT1/SLC2A1 and GLUT3/SLC2A3, were robustly induced, pointing to an increased reliance on glycolytic utilization of glucose. In contrast, a significant repression in bevacizumab-resistant tumors was seen at the level of pyruvate dehydrogenase (PDH) alpha 1 and beta genes that govern the entry of pyruvate into the tricarboxylic acid (TCA) cycle [9]. PDH activity is inhibited by phosphorylation by pyruvate dehydrogenase kinases (PDK). PDK1 and PDK3 isoforms, activity is inhibited by phosphorylation by pyruvate dehydrogenase (PDH) alpha 1 and beta genes that govern the entry of pyruvate into the tricarboxylic acid (TCA) cycle [9].

Exploitation of the increased glycolytic gap: in vivo synergism between bevacizumab and DCA

Based on the marked signature of increased HIF signaling and decreased mitochondrial OXPHOS, we hypothesized that the bevacizumab-resistant tumors would be particularly sensitive to mitochondrial reactivators. The top small molecule candidate from this class is DCA, which inhibits PDK activity, thereby increasing the flux of pyruvate into the mitochondria and promoting glucose oxidation over glycolysis [21, 22]. Taking into
account the well-recognized side effects of antiangiogenic therapy as well as of DCA, for the assessment of the drug combination, we chose a submaximal dose of the antiangiogenic agent (2.5 mg/kg; every 3 days by...
intraperitoneal injection), a strategy which is widely employed in vivo [23]. This approach is also anticipated to increase our ability to detect synergism between the two drugs, both from the standpoint of tumor response and effects on HIF signaling. Indeed, treatment with bevacizumab and DCA dramatically blocked tumor growth compared to each drug alone (Fig. 4A and Supplementary Fig. S1). In order to assess the generalizability of the response, we investigated an additional GBM cell type, U118. The response in U118-based grafts was also much more robust with the combination, compared to the individual drugs (Fig. 4B and Supplementary Fig. S1).

The efficacy of glycolytic inhibitors in overcoming resistance to bevacizumab has been previously proposed [24] without experimental confirmation. DCA and 2-DG were discussed together as part of this concept. However, when 2-DG was tested in parallel to DCA, no additive effect to
bevacizumab was noticed. This was despite the transient effect of 2-DG as a single agent, administered at the concentration described in the literature (Supplementary Fig. S2). Thus, mitochondrial reactivation and direct inhibition of glycolysis have different effects in combination with bevacizumab.

In vitro effects of DCA

Spheroid models provide a system of intermediate complexity between standard two-dimensional culture systems and tumors in vivo because of oxygen and nutrient gradients. Unlike monolayer systems, expanding spheroids mimic the increased avascularity of the in vivo structures growing in presence of bevacizumab. U87 spheroids were generated, as described [25], and grown for 7 days until they reached 0.2 mm³. Spheroids of this size are large enough to allow diffusion of a drug across the spheroid but also are starting to form a small central area of hypoxia and display gradients of nutrients, pH and O₂. Robust divergence of the growth kinetics between DCA-treated and non-treated groups was noticed after 3 days of treatment. This effect was persistent, and from 6 days onward, DCA significantly compromised spheroid expansion (Fig. 4C, D).

Effect of bevacizumab and DCA combination on HIF targets and histological markers of tumor growth

In order to address whether the effect of the combination on tumor growth was primarily determined by increased cell death or decreased proliferation, we performed histological analyses on these tumors, using well-established markers. Necrosis was higher in the treated tumors compared to the untreated ones, but no significant difference was observed between the drugs alone or in combination (Fig. 5). Proliferation rate, as evaluated by quantification of Ki-67 (MIB-1) staining, was significantly lower in the combination group compared to both untreated and bevacizumab-only tumors, suggesting that the effect of the combination was predominantly cytostatic (Fig. 5). We, then, assessed the effects of the drug combination on HIF signaling, using a combination of immunohistochemistry/quantitative RT-PCR (Figs. 5, 6). Surprisingly, while known to increase oxygen consumption in various experimental systems, DCA alone was not sufficient to measurably increase the expression of the HIF targets in vivo. However, in combination with bevacizumab, CA9 expression increased dramatically in the viable U87 tumor cells. In U118, on the other hand, submaximal bevacizumab alone led to a dramatic increase in all HIF targets tested, without further measurable increase in the combination-treated tumors (Fig. 6 and Supplementary Fig. S3). However, the major caveat is that the tumors surviving in the presence of the combination were dramatically smaller and practically stationary, factors that should mitigate the extent of hypoxia.

Discussion

The main goal of our study was to gain a deeper understanding of tumor adaption to bevacizumab, by identifying pathways that are associated with resistance, with a particular focus on metabolic responses. We concentrated on a heterotopic rather than an orthotopic model, primarily to ensure the feasibility of monitoring neoplastic growth and escape. Additionally, as subcutaneous tumors reach significantly larger volumes than their orthotopic counterparts, they are arguably more relevant for modeling advanced and hypoxic malignancies.

In a recently published orthotopic model of GBM, increased hypoxia post-bevacizumab has been reported [24, 26]; however, investigating long-term growth differences is less feasible in such systems. Despite the “classic” status of tumor metabolism in cancer research and its recent revival, no drug that acts primarily at this level has been approved for routine clinical use [27]. DCA, a small molecule which crosses the blood brain barrier [22], showed promising results in a clinical trial in GBM in combination with surgery, temozolomide, and radiation [21], with multiple additional trials currently underway http://clinicaltrials.gov/ct2/results?term= +Dichloroacetate). However, the effect of DCA as a single agent is transient at best, and our tumor models certainly reflect this limitation. A recent study discussed the possibility that bevacizumab treatment should sensitize tumors to both 2-DG and DCA [24], but these predictions have been confirmed only for DCA in our hands. The lack of a measurable additive or synergistic effect of 2-DG was unlikely due to biological inactivity or inadequate dosing as it was transiently effective as a single agent. Questions remain as to the mechanism of DCA-mediated tumor inhibition in the presence of bevacizumab. While DCA was reported to block angiogenesis by itself [21], measurement of mean vessel density did not confirm this in our system.

DCA has been shown to exhibit increased cytotoxic effects under hypoxia in a variety of cell lines [28]. The current paradigm is that DCA accelerates oxygen consumption by mitochondrial reactivation and further decreases local oxygen tension [29], thus posing an additional challenge on tumor cells to survive and/or proliferate. Moreover, it has been demonstrated that in cells ”hardwired” to selectively utilize glycolysis for ATP generation due to mitochondrial DNA.
mutations, forced OXPHOS induced by DCA had a toxic effect. DCA also exhibits synergistic cytotoxicity in vitro in combination with cisplatin and topotecan, two antineoplastic agents known to damage mitochondrial DNA [30]. One could speculate that the downregulation of mitochondrial genes in the bevacizumab-resistant tumors represents a form of mitochondrial dysfunction that sensitizes to the effects of DCA.

Interestingly, the effect of DCA, as a single agent, on HIF targets in xenografts was subtle at best despite its
well-recognized positive effect on oxygen consumption. In contrast, together with bevacizumab, DCA led to increased expression of most HIF targets tested in the surviving tumors versus bevacizumab alone. A possible explanation for these results is that forced OXPHOS induced by DCA in the presence of very low levels of oxygen may lead to increased reactive oxygen species production, which, in turn, may contribute to additional induction of HIF [31]. Additionally, or alternatively, DCA in the presence of bevacizumab may lead to a further decrease in the local oxygen concentration to levels where the induction of HIF targets becomes more evident by quantitative RT-PCR assay. In addition to increased CA9 expression, enhanced expression of the HIF targets PDK1, 3 and GLUT1 was observed in the tumors surviving in the presence of the drug combination in either U87 or U118 cells. This may reflect a more dramatic “last resort” metabolic shift critical for tumor cell survival. In particular, increased expression of PDK1/3 may be part of a “final attempt” by the tumor cells to counteract in part the effect of DCA and inactivate mitochondrial OXPHOS. Such metabolic shifts in tumors surviving in the presence of bevacizumab plus DCA may also provide important clues on how to further increase the efficacy of this combination. For example, one could speculate that the resistant tumors may exhibit at least some sensitivity to a further escalation of DCA concentration although toxicity of this compound may become a limiting factor. Upregulation of tumor-specific CA9 may also play an important role in the survival of the combination-treated tumors as it accelerates the elimination of excess CO₂ generated from the reactivation of the Krebs cycle [25]. Therefore, CA9 inhibitors which have recently shown promising anticancer effects [32, 33] may be regarded as realistic candidates for a third component of a combination strategy.

In conclusion, molecular dissection of tumor adaptation to anti-VEGF agents may offer valuable clues for building more efficient combinations that include targeting cancer metabolism.

**Author’s contributions** Conception and design: M.I. and A.L.H. Acquisition of data: K.K., S.W., H.E.G., H.T., J.L., J.S., A.L.S., R.L., D.S., C.M.D., and M.H. Analysis and interpretation of data: M.I. and A.L.H. Writing, review, and/or revision of the manuscript: M.I. and A.L.H. Administrative, technical, or material support: F.B. Study supervision: M.I. and A.L.H.

**Funding source** The work was supported by grants from Cancer Research United Kingdom [S.W., A.L.H., H.T., R.L., J.L.], METOXIA p-Medicine European Union Framework 7 [D.S., F.B.], Rhodes Scholar [H.G.], Indiana University Cancer Center startup funds, and American Cancer Society [M.I., C.M.D., K.K.].
Conflict of interest  No potential conflicts of interest to declare.

References


